Galcanezumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Trigeminal Neuralgia
Conditions
Trigeminal Neuralgia, Glossopharyngeal Neuralgia
Trial Timeline
Jul 24, 2020 → Jan 4, 2023
NCT ID
NCT04158752About Galcanezumab
Galcanezumab is a approved stage product being developed by Eli Lilly for Trigeminal Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT04158752. Target conditions include Trigeminal Neuralgia, Glossopharyngeal Neuralgia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06085144 | Pre-clinical | Recruiting |
| NCT04158752 | Approved | Completed |
| NCT02959190 | Phase 3 | Completed |
| NCT02797951 | Phase 3 | Completed |
| NCT02836613 | Phase 1 | Completed |
| NCT02614287 | Phase 3 | Completed |
Competing Products
7 competing products in Trigeminal Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Erenumab-Aooe | Amgen | Phase 2 | 51 |
| Rimegepant + Placebo | Pfizer | Phase 2 | 51 |
| BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 49 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |